Cargando…

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease

Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ray, Balmiki, Maloney, Bryan, Sambamurti, Kumar, Karnati, Hanuma K., Nelson, Peter T., Greig, Nigel H., Lahiri, Debomoy K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026402/ https://www.ncbi.nlm.nih.gov/pubmed/32066688 http://dx.doi.org/10.1038/s41398-020-0709-x

Ejemplares similares

Correction: Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Rivastigmine Lowers Aβ and Increases sAPPα Levels, Which Parallel Elevated Synaptic Markers and Metabolic Activity in Degenerating Primary Rat Neurons
por: Bailey, Jason A., et al.
Publicado: (2011)

Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue
por: Ray, Balmiki, et al.
Publicado: (2016)

Autism as early neurodevelopmental disorder: evidence for an sAPPα-mediated anabolic pathway
por: Lahiri, Debomoy K., et al.
Publicado: (2013)

Increased Secreted Amyloid Precursor Protein-α (sAPPα) in Severe Autism: Proposal of a Specific, Anabolic Pathway and Putative Biomarker
por: Ray, Balmiki, et al.
Publicado: (2011)

Human primary mixed brain cultures: preparation, differentiation, characterization and application to neuroscience research
por: Ray, Balmiki, et al.
Publicado: (2014)

Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease
por: Tweedie, David, et al.
Publicado: (2012)

PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer’s amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE)
por: Lahiri, Debomoy K, et al.
Publicado: (2013)

Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5′-untranslated region: Implications in Alzheimer’s disease
por: Long, Justin M., et al.
Publicado: (2018)

Human microRNA (miR-20b-5p) modulates Alzheimer’s disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer’s biomarkers
por: Wang, Ruizhi, et al.
Publicado: (2022)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
por: Li, Yazhou, et al.
Publicado: (2012)

Novel Roles of Amyloid-Beta Protein Precursor Metabolites in Fragile X Syndrome and Autism
por: Westmark, Cara J., et al.
Publicado: (2016)

Novel Contribution of Secreted Amyloid-β Precursor Protein to White Matter Brain Enlargement in Autism Spectrum Disorder
por: Sokol, Deborah K., et al.
Publicado: (2019)

A serine protease KLK8 emerges as a regulator of regulators in memory: Microtubule protein dependent neuronal morphology and PKA-CREB signaling
por: Konar, Arpita, et al.
Publicado: (2018)

FMRP Regulates the Nuclear Export of Adam9 and Psen1 mRNAs: Secondary Analysis of an N(6)-Methyladenosine Dataset
por: Westmark, Cara J., et al.
Publicado: (2020)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Lithium alters expression of RNAs in a type-specific manner in differentiated human neuroblastoma neuronal cultures, including specific genes involved in Alzheimer’s disease
por: Maloney, Bryan, et al.
Publicado: (2019)

Evidence of a Novel Mechanism for Partial γ-Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid β Protein
por: Barnwell, Eliza, et al.
Publicado: (2014)

Repeated electromagnetic field stimulation lowers amyloid-β peptide levels in primary human mixed brain tissue cultures
por: Perez, Felipe P., et al.
Publicado: (2021)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Functional microRNAs in Alzheimer’s disease and cancer: differential regulation of common mechanisms and pathways
por: Holohan, Kelly N., et al.
Publicado: (2013)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

Esophagectasis Related to Rivastigmine
por: Sasaki, Osamu, et al.
Publicado: (2019)

Repression of Alzheimer's beta-Secretase
por: Liao, Francesca-Fang, et al.
Publicado: (2013)

γ-Secretase in Alzheimer’s disease
por: Hur, Ji-Yeun
Publicado: (2022)

The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease
por: MacLeod, Ruth, et al.
Publicado: (2015)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Nuclear factor-kappa B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model
por: Srinivasan, Mythily, et al.
Publicado: (2018)

Time-dependent cytokine and chemokine changes in mouse cerebral cortex following a mild traumatic brain injury
por: Tweedie, David, et al.
Publicado: (2020)

Enhancing α-secretase Processing for Alzheimer’s Disease—A View on SFRP1
por: Tang, Bor Luen
Publicado: (2020)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease
por: Kim, Hyeyun, et al.
Publicado: (2016)

M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera
por: Konar, Arpita, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lr41vqibbrh8nou56gcedl786v